MX2024009168A - Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico. - Google Patents

Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico.

Info

Publication number
MX2024009168A
MX2024009168A MX2024009168A MX2024009168A MX2024009168A MX 2024009168 A MX2024009168 A MX 2024009168A MX 2024009168 A MX2024009168 A MX 2024009168A MX 2024009168 A MX2024009168 A MX 2024009168A MX 2024009168 A MX2024009168 A MX 2024009168A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
administration
anticancer drug
composition including
phthalazinone derivative
Prior art date
Application number
MX2024009168A
Other languages
English (en)
Spanish (es)
Inventor
Yeongran Yoo
Myongjae Lee
Won Sik Lee
Kyoung Soo Ha
Eun - Jihn Roh
Minju Hong
Sungyeon Choi
Jeong Eun Kim
In - Gyu Je
Jong - Ha Lim
Original Assignee
Idience Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idience Co Ltd filed Critical Idience Co Ltd
Publication of MX2024009168A publication Critical patent/MX2024009168A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2024009168A 2022-01-25 2023-01-25 Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico. MX2024009168A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263302834P 2022-01-25 2022-01-25
PCT/IB2023/000030 WO2023144626A1 (en) 2022-01-25 2023-01-25 Pharmaceutical composition including phthalazinone derivative for co-administration with anticancer drug

Publications (1)

Publication Number Publication Date
MX2024009168A true MX2024009168A (es) 2024-08-09

Family

ID=87470837

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024009168A MX2024009168A (es) 2022-01-25 2023-01-25 Composicion farmaceutica que incluye derivado de ftalazinona para coadministracion con farmaco antineoplasico.

Country Status (14)

Country Link
US (1) US20250120970A1 (cg-RX-API-DMAC7.html)
EP (1) EP4469051A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025505381A (cg-RX-API-DMAC7.html)
KR (1) KR20240138069A (cg-RX-API-DMAC7.html)
CN (1) CN118613264A (cg-RX-API-DMAC7.html)
AU (1) AU2023210923A1 (cg-RX-API-DMAC7.html)
CA (1) CA3249330A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002218A1 (cg-RX-API-DMAC7.html)
IL (1) IL314334A (cg-RX-API-DMAC7.html)
JO (1) JOP20240162A1 (cg-RX-API-DMAC7.html)
MA (1) MA66598A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024009168A (cg-RX-API-DMAC7.html)
TW (1) TW202339753A (cg-RX-API-DMAC7.html)
WO (1) WO2023144626A1 (cg-RX-API-DMAC7.html)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102372706A (zh) * 2010-08-09 2012-03-14 江苏恒瑞医药股份有限公司 酞嗪酮类衍生物、其制备方法及其在医药上的应用
EP2833883A4 (en) * 2012-04-06 2015-12-23 Indus Pharmaceuticals Inc NOVEL COMPOSITIONS OF COMBINATIONS OF NONCOVALENT DNA BINDER AND CANCER-INHIBITING AND / OR INFLAMMATORY ACTIVE SUBSTANCES AND THEIR USE IN THE TREATMENT OF ILLNESSES
KR101670126B1 (ko) * 2013-09-13 2016-10-27 일동제약(주) 신규 프탈라지논 유도체 및 그 제조방법
US12036222B2 (en) * 2018-04-04 2024-07-16 The Wistar Institut of Anatomy and Biology Methods of treating cancers overexpressing CARM1 with EZH2 inhibitors and a PARP inhibitor
WO2021214502A1 (en) * 2020-04-21 2021-10-28 Idience Co., Ltd. Process for preparing a phthalazinone derivative and intermediates thereof
KR102913343B1 (ko) * 2020-04-21 2026-01-15 아이디언스 주식회사 프탈라지논 화합물의 결정형

Also Published As

Publication number Publication date
TW202339753A (zh) 2023-10-16
CA3249330A1 (en) 2023-08-03
JP2025505381A (ja) 2025-02-26
EP4469051A1 (en) 2024-12-04
KR20240138069A (ko) 2024-09-20
CN118613264A (zh) 2024-09-06
MA66598A1 (fr) 2024-11-29
IL314334A (en) 2024-09-01
CL2024002218A1 (es) 2024-12-20
WO2023144626A1 (en) 2023-08-03
EP4469051A4 (en) 2025-12-17
AU2023210923A1 (en) 2024-07-25
US20250120970A1 (en) 2025-04-17
JOP20240162A1 (ar) 2024-07-23

Similar Documents

Publication Publication Date Title
CR20230024A (es) Derivados de quinoxalina como fármacos contra el cáncer
MX2024006074A (es) Inhibidor de parp1 selectivo y aplicacion del mismo.
WO2023088497A3 (zh) 一种氧化氮供体型贝前列素类衍生物及其药物组合物和用途
CO2022008606A2 (es) Derivados de piridopirimidinona como antagonistas de ahr
MX2022008479A (es) Combinaciones de brimonidina de dosis baja y usos de las mismas.
NZ754764A (en) Pyrimidine tricyclic enone derivatives for inhibition of rorγ and other uses
MX2023005763A (es) Composiciones y metodos para la administracion dermica profunda de farmacos.
MX2022014921A (es) Administracion concomitante de modulador del receptor de glucocorticoides relacorilant y paclitaxel, un sustrato dual de cyp2c8 y cyp3a4.
AR110800A1 (es) MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2’-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA
MX2026000796A (es) Composiciones de administracion mejorada de epinefrina y profarmacos
EP4342985A3 (en) Pharmaceutical composition for preventing or treating cancer comprising anticancer virus and hydroxyurea as effective components
MX2022004739A (es) Compuesto novedoso y composicion farmaceutica para prevencion o tratamiento de cancer que comprende el mismo.
WO2021222584A3 (en) Inhibition of sars-cov-2 viral entry through administration of lactoferrin and uses thereof
MX2021014830A (es) Conjugados de compuestos que comprenden nitrogeno heteroaromatico donador de pares de electrones pi.
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
JOP20240162A1 (ar) تركيبة صيدلية تتضمن مشتق فثالازينون للإعطاء المشترك مع عقار مضاد للسرطان
MX2023012483A (es) Formulaciones farmaceuticas transdermicas para el tratamiento del dolor cronico.
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
RU2011129815A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
RU2011113733A (ru) Производные 1-амино-алкилциклогексана для лечения когнитивного нарушения при шуме в ушах
PH12023553121A1 (en) Benzamide derivative, method for preparing same, and pharmaceutical composition for prevention or treatment of cancer containing same as active ingredient
WO2024006971A3 (en) Antimalarial compounds
MX2024008873A (es) Usos y metodos para promover el aumento de la masa y funcion mitocondrial.